Research and Clinical Trials on Risperidone (Risperdal)

By Dr Greg Mulhauser
avatar image

This list of current clinical research trials on Risperidone (Risperdal) is followed by a short set of abstracts from the most recent research articles published on the drug.

Article Contents

Risperidone (Risperdal) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Risperidone (Risperdal).

 

Get These Clinical Trials as a Newsfeed

Risperidone:     Get the Risperidone clinical trials feed.    Add the Risperidone clinical trials feed to your My Yahoo! page.    Add the Risperidone clinical trials feed to your MyMSN page.

Current Research Literature on Risperidone (Risperdal)

Here are abstracts for some of the latest research articles to have appeared on Risperidone (Risperdal):

[Weight gain in patients with schizophrenia and schizoaffective disorder induced by the long-term treatment with atypical antipsychotics.]

Zh Nevrol Psikhiatr Im S S Korsakova. 2008; 108(9): 52-56
Gorobets LN
To specify the effect of different atypical antipsychotics on weight gain, 346 patients with schizophrenia and schizoaffective disorder have been examined. The influence of risperidone (88 patients), olanzapine (84 patients), clozapine (61 patients), quetiapine (68 patients) and amisulpiride (45 patients) used as a monotherapy has been studied during 1,5 years. Frequency of weight gain for every drug and peculiarities of the dynamics of pharmacogenic weight gain and body mass index in some stages (after 3, 6, 12 and 18 months) have been revealed. The data obtained allow to conclude that the long-term therapy with olanzapine, clozapine and risperidone exert a more marked influence on the body mass as compared to quetiapine and amisulpiride regardless of the patient's sex.

[The study of therapeutic efficacy of two forms of risperidone - rileptid and rispolept in patients with schizophrenia.]

Zh Nevrol Psikhiatr Im S S Korsakova. 2008; 108(8): 29-33
Akhapkin RV
Generic drugs represent a big part of the Russian pharmaceutical market, a number of registered copies of the same drug manufactured by different pharmaceutical companies being estimated as several tens of drugs that does not mean their equally high quality and complete interchangeability. A choice of optimal price-to-quality ratio of a drug among a great number of analogues is possible only with taking into account a number of factors related to a manufacturer, a drug and a patient. The most important index of interchangeability of generic drugs is their therapeutic equivalence to the original one. A study aimed to compare the therapeutic equivalence of two preparations of risperidone - original rispolept and generic rileptid has been carried out. The comparison of efficacy and tolerability of the therapy has not revealed differences both in any of the parameters and in any stages of the study. In conclusion, the full therapeutic equivalence of generic drug rileptid to original rispolept is revealed.

Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence.

Psychiatr Serv. 2008 Oct; 59(10): 1175-83
Baldessarini R, Henk H, Sklar A, Chang J, Leahy L
OBJECTIVE: Because treatments for bipolar disorder include a growing number of psychotropic agents, the authors evaluated psychotropic polytherapy and adherence to treatment among U.S. patients with bipolar disorder. METHODS: National health plan claims data (2000-2004) were used to identify patients diagnosed as having bipolar disorder who had continuous benefits and had not been prescribed medication for bipolar disorder for six months or more. The study compared drugs dispensed to these patients initially and at one year and characterized patients who were adherent to mood-stabilizers. RESULTS: A total of 7,406 patients had a bipolar disorder: bipolar I (55%), bipolar II (15%), or bipolar disorder not otherwise specified (30%). Women represented 57% of the sample; mean+/-SD age was 35.4+/-12.4 years. Initial prescription fills involved one psychotropic agent in 67% of patients, and two or more psychotropics (polytherapy) in 33%. Initial prescription drug selections involved: antidepressants > anticonvulsants >or= antipsychotics > sedatives > lithium; initial mood stabilizer use ranked: valproate > lithium > carbamazepine or oxcarbazepine > lamotrigine; antipsychotics ranked: olanzapine > quetiapine >or= risperidone > ziprasidone > aripiprazole > clozapine. Rankings were similar at one year, when only 31% of patients received monotherapy (a 2.2-fold decline), 32% received polytherapy, and 37% received no psychotropics. Initially patients received 1.42 psychotropic drugs per person; at one year, patients received 175, and at both times polytherapy was less likely with lithium than with anticonvulsants. In multivariate modeling, one-year mood stabilizer use was greater with the following: older age, type of mood stabilizer (lamotrigine > valproate > carbamazepine or oxcarbazepine > lithium) and was associated with more psychiatric office and emergency visits, clinician type (more common with psychiatrists than with primary care physicians), and nonuse of off-label anticonvulsants. CONCLUSIONS: Polytherapy was used by one-third of patients initially and at one year, antidepressant use was highly prevalent initially and later, but lack of treatment was prevalent at one year. Plausible clinical and treatment factors were associated with sustained mood stabilizer adherence.

Changing trends in pediatric antipsychotic use in Florida's Medicaid program.

Psychiatr Serv. 2008 Oct; 59(10): 1162-8
Constantine R, Tandon R
OBJECTIVE: This study describes the changing trends in antipsychotic use among youths aged 18 years and younger and in age subgroups (zero to five, six to 12, and 13 to 18 years) in the Florida Medicaid program. METHODS: The study used Florida Medicaid claims data associated with approximately 1.2 million children and adolescent enrollees per year to describe monthly antipsychotic use from July 2002 to December 2005. A preliminary examination of trends indicated that antipsychotic use might be different for the periods before May 2004 and after April 2004. For this reason, piecewise regression was used to compare the trends for these two periods. RESULTS: This study found significant increases in the use of antipsychotic medications for all three age groups from July 2002 to April 2004. The greatest rate of growth was for the 13- to 18-year age group, and the least rate of growth was for the zero- to five-year age group. From May 2004 to December 2005 antipsychotic utilization trends were flat for youths age 18 years and younger and for the six- to 12-year and the 13- to 18-year age groups. For preschool-age children (the zero- to five-year age group), there was a slight but significant decline in antipsychotic use. Significant changes were also observed in the specific second-generation antipsychotic agents prescribed. Although risperidone remained the most frequently prescribed antipsychotic, its use declined significantly from May 2004 to December 2005. Olanzapine use also declined during this period. On the other hand, aripiprazole use increased significantly throughout the study period, with usage among the 13- to 18-year age group almost equaling that of risperidone by December 2005. CONCLUSIONS: The lack of growth in antipsychotic prescribing after the spring of 2004 represents a significant departure from historical trends. Although some in-state policies may have affected these trends, it appears that the timing and extent of the changes occurred shortly after the Food and Drug Administration required warnings on second-generation antipsychotic medications related to weight gain, glucose levels, and diabetes. They appeared immediately after the black box warning for pediatric antidepressant medications, and they appeared shortly after the Joint American Diabetes and American Psychiatric Association Consensus Statement. These factors suggest the existence of a prescribing community that is responsive to evidence and to professional and regulatory actions based on it.

Risperidone attenuates local as well as systemic inflammatory responses to ameliorate diet-induced severe necrotic pancreatitis in mice: it may provide a new therapy for acute pancreatitis.

J Pharmacol Exp Ther. 2008 Oct 1;
Yamaguchi I, Hamada K, Yoshida M, Isayama H, Kanazashi S, Takeuchi K
In a previous paper, we showed that a selective 5-HT2A antagonist, risperidone, ameliorated cerulein-induced edematous pancreatitis in mice. In the present paper, young female mice were fed a choline-deficient ethionine-supplemented diet. All the mice developed severe necrotic pancreatitis, and approximately 50% of them died within 4 days. Serum levels of proinflammatory IL-6 significantly increased on day 3, and returned towards the control on day 4 of CDE treatment. The time course of IL-6 levels paralleled those of plasma amylase and lipase activities. On the other hand, platelet counts significantly decreased on day 3, and the change became more marked on day 4, coinciding with mortality and histological alterations of the pancreas (edema, inflammatory cell infiltration, necrosis). Preceding these changes, plasma levels of 5-HIAA increased on feeding a CDE diet to reach a peak on day 3, and returned towards the control on day 4. Risperidone (0.1~3.2 mg/kg twice a day) hardly affected the 5-HIAA levels, but dose-dependently attenuated the serum IL-6 levels, plasma amylase/lipase levels, platelet counts, histological alterations and mortality of diet-induced pancreatitis mice. These results are discussed in relation to the pathogenesis of acute pancreatitis. We thus speculate that acinar cell injury triggers local inflammatory reactions, and, if coincided with enhanced IL-6 release, leads to a systemic inflammatory response syndrome (SIRS) which is responsible for the mortality. In addition, it is suggested that diet-induced 5-HT release and 5-HT2A receptor activation are involved in the whole process of pancreatitis development. Risperidone may provide a new therapy for the disease.

 

This page was last reviewed by Dr Greg Mulhauser, Friday, 4 July 2008.

The URL of this page is:
http://counsellingresource.com/medications/trials-and-research/risperidone-research.html